Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

The stock market—and biotech insiders—reacted negatively to the allegedly forced resignation of CBER Director Peter Marks, ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...

Bluebird bio on Friday confirmed it has received an unsolicited take-over offer from the Ireland-based investment firm Ayrmid ...

According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...

While AI offers remarkable efficiency, the pharmaceutical industry must address concerns about “black box” predictions – AI ...

Industry updates and investment insights—including investor behavior and fundraising advice—were among the topics experts ...

While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Werner held roles at Bristol Myers Squibb, AstraZeneca and Novartis before landing at Alltrna, where she works to develop tRNA-based treatments for a range of diseases.

The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...